Navigation Links
NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011
Date:5/4/2011

LAWRENCE, Mass., May 4, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported financial results for the first quarter of 2011 ended March  31, 2011, with total revenue above the top end of its guidance range.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

Net revenue for first quarter of 2011 increased 25 percent to a record $50.6 million compared with revenue of $40.4 million for the first quarter of 2010.  The increase was primarily driven by continued strong growth in the Home as a result of increased adoption of home hemodialysis with the NxStage System One™, and solid performance in Critical Care and In-Center.

Home revenue for the first quarter increased 37 percent to a record $26.0 million compared with revenues of $19.0 million for the first quarter of 2010.  

Critical Care revenue increased 23 percent to $7.4 million for the first quarter of 2011 compared with revenues of $6.1 million for the first quarter of 2010.  Revenue in the In-Center market increased to $17.1 million for the first quarter of 2011 compared with revenues of $15.3 million for the first quarter of 2010.  

"In Q1, we continued our trend of delivering solid operating and financial results, and top line revenue ahead of our expectations," stated Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc. "We continue to be encouraged by evidence that our strategy to increase adoption of home hemodialysis with the System One continues to gain traction. We're focused on maintaining our growth momentum across our business while continuing to execute against our long-term growth strategy, which includes creating appropriate reimbursement for home hemodialysis that is both simple and predictable. We believe we are well positioned to deliver contin
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. ULURU Inc. Reports Second Quarter 2008 Financial Results
10. Immtech Reports Fiscal First Quarter 2009 Results
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... N.Y., Aug. 1, 2011 Nycomed US Inc. ("Nycomed US") ... and Chief Executive Officer and member of the Board for ... the closing of the acquisition of Nycomed A/S by Takeda ... Bailey to the newly created position of Chief Operating Officer, ...
... a biopharmaceutical company pioneering a novel class of ... an entirely new class of naturally occurring human ... of these naturally supercharged human proteins enable biologic ... cells. This new class of proteins is the ...
... in the body, then alarm bells start ringing. ... disease and type 2 diabetes, formerly called adult-onset diabetes. ... then they might be able to treat such diseases ... colleagues at the Helmholtz-Zentrum Dresden-Rossendorf and the university in ...
Cached Biology Technology:Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 2Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 3Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 2Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 3In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3
(Date:7/9/2014)... Tampa, Fla. (July 9, 2014) Emerging fungal ... any other parasitic group, causing population declines of ... from the University of South Florida published in ... amphibians can acquire behavioral or immunological resistance to ... population declines. , "Acquired resistance is important ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... replace lost teeth with titanium dental implants could be improved. ... at micro level but also at nano level, researchers at ... method that could shorten the healing time for patients. , ... conductivity of the implant allows us to affect the body,s ...
... new type of cell in the immune system. ... belongs to a family of T-cells that play a critical ... could ultimately lead to the development of novel drugs that ... It is also potentially significant for many other ...
... 2011 Numera, a leading provider of innovative ... entered into a strategic partnership with HealthTrio LLC. ... integrate objective, biometric information from dozens of consumer-preferred ... Health Record (PHR). This new functionality will be ...
Cached Biology News:Healing times for dental implants could be cut 2New cell type offers immunology hope 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 3